ABIONYX Announces Positive Clinical Findings for CER-001 in Treating COVID-19, Published in Biomedecines, Demonstrating That CER-001 Limits Inflammation Effects

TOULOUSE, France--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible) (Paris:ABNX), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, announced today the publication in Biomedecines of the first clinical data demonstrating that CER-001 limits inflammation effects in acute inflammatory conditions such as COVID-19. COVID-19 is associated with respiratory symptoms characterized by acute lung injur